MS epatient meets German clinical trial

Written by Silja on 5 January 2012 in epatients - 7 Comments

Speedy, well-run trials giving birth to break through novel therapies is what we all want. Clinical trials are thus the most crucial collaboration between patients with pharma. When Birgit was asked to participate in a clinical trial for an oral MS treatment, she was quiet positive at first. The therapy sounded promising, the side effects manageable and the objective to further scientific advancement was appealing to her.

Unfortunately, this enthusiasm was quickly replaced with doubts. Somehow the information on potential side effects she received from her doctor did not match what other patient were saying online. Somehow she felt she did not completely understand the informed consent and clinical protocol she was asked to sign…and that no one really cared to sit down and sincerely address her doubts. Finally, the burden of participation in terms of costs and time combined with her growing doubts led her to pull out and not participate in the trial.

Birgit’s testimony in the video below is a typical example of the new epatient decision process. Pharma now needs to convince patients of the benefits of their clinical trial, address their doubts  as well as meet their expectations for transparency and support. It indicates a crucial shift in how clinical trials need to be run and communicated in the future.

7 Comments on "MS epatient meets German clinical trial"

  1. Dan Sfera 12 January 2012 at 2 h 50 min ·

    This is just further proof of how the game is changing. If pharma wants to improve clinical trial participation, the communication between pharma and research site and ultimately trial participant must improve.

  2. Lakeesha Szalankiewicz 23 August 2012 at 8 h 08 min ·

    MS treatment is still not 100% successful. But with the advent of modern stem cells, i think in the near future we would be able to cure it permanently..`*`”

    Best regards

  3. Frankie Rosinski 13 November 2012 at 4 h 57 min ·

    I believe that today we would not have a one pill that would treat Multiple Sclerosis but over time we would finally find a permanent cure for this disease.-

    Brand new piece of writing on our own blog site

  4. James Kilcrest 11 February 2013 at 20 h 55 min ·

    Dr. Wiginton is among the 45 participants in a southwestern Utah-based clinical trials – the first of its kind in the south-west – to investigate the use of the delivery system for radiation. His post-lumpectomy therapy lasted one third of the length of a session of radiation typical of a patient with breast cancer.If you are willing to use the brain tumor, I think it’s a pretty safe bet for use in a breast, said Wiginton. Dr. Wiginton, including the study by Dr. Dan Garwood, associate professor of radiation oncology, said he hopes that the procedure will be successful and to offer new options of radiotherapy for breast cancer patients.`

    Most popular short article provided by our very own web page

  5. Tyler Hardges 22 March 2013 at 20 h 35 min ·

    Multiple sclerosis (MS) is a disease in which the nerves of the central nervous system (brain and spinal cord) to degenerate. Myelin, which provides a covering or insulation for nerves, improves the conduction of impulses along the nerves and also is important for maintaining the health of the nerves. In multiple sclerosis, inflammation causes the myelin to disappear. Consequently, the electrical impulses that travel along the nerves decelerate, that is, become slower. In addition, the nerves themselves are damaged. As more and more nerves are affected, a person experiences a progressive interference with functions that are controlled by the nervous system ;

    Most popular blog post provided by our personal blog site
    <' as vision, speech, walking, writing, and memory.

  6. nba 2k16 mt giveaway 7 April 2016 at 3 h 09 min ·

    Seriously….such a invaluable internet site.|

  7. 7 April 2019 at 2 h 09 min ·

    So far, clinical studies in primary progressive MS (PPMS) have failed to meet their primary efficacy endpoints. To some extent this might be attributable to the choice of assessments or to the selection of the study population.

Leave a Comment